Q1 2026 · 13F-HR
JOHNSON & JOHNSON (JNJ)holdings as filed
Filed 2026-05-13 · accession 0000904454-26-000280
$652.4M
Reported value
16
Positions
2026-03-31
Period end
The Brief · JOHNSON & JOHNSON (JNJ) · Q1 2026
AI · grounded in 13F
JOHNSON & JOHNSON (JNJ) closed its position in Rallybio Corporation RLYB with a reduction of $2.49M. The fund also exited its holding in Lyell Immunopharma, Inc. LYEL, selling $1.27M. Additionally, the fund trimmed its stake in Nano-X Imaging Ltd. NNOX by 47.4%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 74366E102 | PTGX | Protagonist Therapeutics Inc. | $258.1M | 39.6% | 2,449,183 | Common | SHARED |
| 63009J107 | NBTX | Nanobiotix S.A. | $173.6M | 26.6% | 5,623,816 | Common | SHARED |
| G59665102 | MGTX | MeiraGTx Holdings plc | $57.5M | 8.82% | 6,641,064 | Common | SHARED |
| 75383L102 | RAPP | Rapport Therapeutics, Inc. | $55.8M | 8.56% | 1,784,517 | Common | SHARED |
| 126638105 | CVRX | CVRx, Inc. | $38.1M | 5.84% | 4,024,861 | Common | SHARED |
| 21217B100 | CTNM | Contineum Therapeutics Inc. | $25.8M | 3.96% | 1,979,173 | Common | SHARED |
| 52490G102 | LEGN | Legend Biotech Corporation | $14.7M | 2.26% | 814,586 | Common | SHARED |
| 98401F105 | XNCR | Xencor, Inc. | $9.0M | 1.38% | 748,062 | Common | SHARED |
| 74276L105 | PRCT | Procept BioRobotics Corporation | $9.0M | 1.37% | 357,939 | Common | SHARED |
| 31189P102 | FATE | Fate Therapeutics, Inc. | $4.1M | 0.62% | 3,379,064 | Common | SHARED |
| 640979100 | NMRA | Neumora Therapeutics, Inc. | $3.6M | 0.55% | 1,849,445 | Common | SHARED |
| 75120L209 | RLYB | Rallybio Corporation | $1.4M | 0.21% | 152,901 | Common | SHARED |
| 929033207 | VOR | Vor Biopharma, Inc. | $958,579 | 0.15% | 53,732 | Common | SHARED |
| 34385P108 | LAB | Standard BioTools, Inc. | $286,791 | 0.04% | 311,967 | Common | SHARED |
| M70700105 | NNOX | Nano-X Imaging Ltd. | $189,668 | 0.03% | 83,554 | Common | SHARED |
| 007002207 | ACET | Adicet Bio, Inc. | $155,125 | 0.02% | 22,779 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.